title: Early Clinical Detection of Pharmacologic Response in Insulin Action in a Nondiabetic Insulin-Resistant Population.
abstract: BACKGROUND
  Insulin resistance heightens the risk for type 2 diabetes mellitus and cardiovascular disease. Amelioration of insulin resistance may reduce this risk. The thiazolidinedone class of insulin sensitizers improves insulin action in individuals with insulin-resistant diabetes and nondiabetic individuals. However, there are few reports on the time of onset of such effects independent of reversal of glucotoxicity.
  
  
  OBJECTIVE
  The goal of our study was to test whether the thiazolidinedione pioglitazone has prominent early metabolic effects that can be detected in an obese, nondiabetic, insulin-resistant population.
  
  
  METHODS
  We conducted a randomized, double-blind, placebo-controlled, parallel-group trial in men with nondiabetic insulin resistance using a hyperinsulinemic euglycemic clamp technique (at low and high doses of insulin at 10 and 40 mU/m(2)/min, respectively). The patients were given 30 mg daily oral pioglitazone or placebo for 28 days. Patients underwent a baseline clamp before initiation of treatment, and again at 14 and 28 days of treatment.
  
  
  RESULTS
  Compared with placebo, under high-dose hyperinsulinemia, pioglitazone led to significant increases in glucose disposal rates (GDR) of 1.29 mg/kg/min (90% CI, 0.43-2.15; 39%; P=0.008) that were detectable at 2 weeks of treatment and persisted at 4 weeks of treatment. Under low-dose hyperinsulinemia, significant increases in GDR of 0.40 mg/kg/min (90% CI, 0.17-0.62; 95%; P=0.003) were observed at 4 weeks of treatment. These responses were accompanied by robust suppression of free fatty acids under hyperinsulinemic conditions, and by significant increases in circulating basal total adiponectin at 2 and 4 weeks of treatment.
  
  
  CONCLUSIONS
  Significant changes in insulin action across multiple insulin-sensitive tissues can be detected within 2 weeks of initiation of insulin-sensitizing therapy with pioglitazone in obese patients with nondiabetic insulin resistance. ClinicalTrials.gov identifier: NCT01115712.
authors.affiliation: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ.
authors.forename: Sudha S
authors.initials: SS
authors.lastname: Shankar
authors.affiliation: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ.
authors.forename: R Ravi
authors.initials: RR
authors.lastname: Shankar
authors.affiliation: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ.
authors.forename: Radha A
authors.initials: RA
authors.lastname: Railkar
authors.affiliation: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ.
authors.forename: Chan R
authors.initials: CR
authors.lastname: Beals
authors.affiliation: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ.
authors.forename: Helmut O
authors.initials: HO
authors.lastname: Steinberg
authors.affiliation: Merck Research Laboratories, Merck & Co., Inc., Kenilworth, NJ.
authors.forename: David E
authors.initials: DE
authors.lastname: Kelley
keywords: free fatty acids; glucose clamp; insulin resistance; insulin sensitivity; nondiabetic; pioglitazone